Clinical Trial Update: A Double-blind, Intra-individual Comparison, POC Trial of AC-203 in EB Patients [Phase 2]

View source ↗

Summary

Phase 2 double-blind intra-individual trial of AC-203 in inherited Epidermolysis Bullosa completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Inherited Epidermolysis Bullosa

Drugs mentioned

• AC-203

Snippet

Sponsor: TWi Biotechnology, Inc. | Conditions: Inherited Epidermolysis Bullosa | Phase 2 | Status: COMPLETED